Least 24 hours after the ELAD Treatment Period is ended (end of Day 7 for Controls) and up toīoth End of Study Days 28 and 91 following Randomization. Points from End of Study Day 1 MELD score (for both the ELAD and Control groups) until at Progression is defined as death or the first observed increase of at least 5 Up to Study Day 91, and the proportion of progression-free survivors (PFS) up to Study DaysĢ8 and 91. Measured using the Model for End Stage Liver Disease (MELD)-based time to progression (TTP) Secondary objectives are to determine the proportion of survivors at Study Days 28 and 91.Įxploratory objectives are to evaluate the ability of ELAD to stabilize liver function, Through VTI-208 study termination (after the last surviving enrolled subject completes Study To overall survival (OS) of subjects with a clinical diagnosis of alcohol-induced liverĭecompensation (AILD) up to at least Study Day 91, with follow-up Protocol VTI-208E providingĪdditional survival data up to a maximum of 5 years that will be included, as available, The primary objective of the study is to evaluate safety and efficacy of ELAD® with respect Vice Provost for Undergraduate Education.Office of Vice President for Business Affairs and Chief Financial Officer.Office of VP for University Human Resources.Stanford Woods Institute for the Environment.Stanford Institute for Economic Policy Research (SIEPR).Institute for Stem Cell Biology and Regenerative Medicine.Institute for Human-Centered Artificial Intelligence (HAI).Institute for Computational and Mathematical Engineering (ICME).Freeman Spogli Institute for International Studies.Stanford Doerr School of Sustainability.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |